Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib rollover study
NCT03890731Phase 2Completed
- Sponsor
- Bayer
- Start
- Apr 2019
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of regorafenib in solid tumor, sponsored by Bayer. Primary endpoints: Number and Severity of Participants With Adverse Events and Serious Adverse Events up to 46 months, Severity (by Worst Grade) of Participants With Adverse Events and Serious Adverse Events up to 46 months and 2 more. Started Apr 2019; status: completed.
02
Drugs
regorafenib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03890731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03890731.